Maintain existing position size; no new capital or averaging before the China GDP print (~Oct 21) or Q3 earnings. If upside trigger fires (close > 13.42 on expanding volume), scale toward Overweight in increments; if downside trigger fires (close < 11.80), exit full position.
NEXA is in a coiled six-week range ($11.80–$13.30) with the evidence genuinely split: a nascent below-zero MACD bullish cross (histogram +0.08) and a rising 200 SMA (12.83) converging on price argue for repair, while the price sits below all moving averages (50 SMA 13.42 declining), the RSI is dead-neutral at 45.88, and the June-onward lower-high sequence (14.25 → 13.29 → 13.20) remains intact. Fundamentals are equally balanced — cheap 3.74x forward P/E and ~$371M TTM FCF versus stalled deleveraging (net debt up to $1,346M) and one-off-dependent FY2025 profits — and a binary China GDP print is five days out. With ATR compressed to $0.57 (a squeeze that typically resolves fast) and neither bulls nor bears in control at $12.48 mid-range, entering now is a coin-flip; the disciplined play is to hold the existing position and act mechanically on the predefined triggers: exit on a close below 11.80 (bearish measured move toward 10.75–11.00), scale up only on a close above 13.42 with volume confirmation (target zone 14.25–16.00).
Position Sizing: Maintain existing position size; no new capital or averaging before the China GDP print (~Oct 21) or Q3 earnings. If upside trigger fires (close > 13.42 on expanding volume), scale toward Overweight in increments; if downside trigger fires (close < 11.80), exit full position.
FINAL TRANSACTION PROPOSAL: HOLD
============================================================
FINAL DECISION (NEXA, 2026-10-16):
============================================================
Hold
Elapsed: 472s
```
…
NEXA has completed a dramatic round trip of sentiment over the past 12 months. The stock bottomed near $5.20–5.54 in October–November 2025, launched an extraordinary rally to an intraday peak of $16.72 (2026-05-06), and has since spent roughly four months in a broad corrective/consolidation phase. As of the latest verified close ($12.48 on 2026-10-15), the stock sits in a tightening, range-bound equilibrium roughly 24% below its closing high ($16.02, 2026-06-01) but still ~134% above its October 2025 base.
The current technical picture is mixed-to-neutral with early signs of momentum repair: price is pinned below its falling 50 SMA but hovering just under a rising 200 SMA, the MACD has just printed a bullish crossover while still in negative territory, RSI is dead-neutral at ~46, and ATR compression signals the market is coiling for its next directional move. This is a classic "decision window" setup — HOLD is the appropriate stance until the range resolves.
---
NEXA is in a high-information waiting zone: a six-week range ($11.80–$13.30), a volatility squeeze (ATR −29% in a month, Bollinger bands contracting), a nascent below-zero MACD bullish crossover, neutral RSI, and a rising 200 SMA converging on price from below while the 50 SMA presses down from above. Neither bulls nor bears currently control the tape. Entering now is a coin-flip against well-defined triggers; the disciplined play is to let the range resolve.
FINAL TRANSACTION PROPOSAL: HOLD**
---
Bull case:
1. Valuation is cheap: Forward P/E of 3.7x, P/B 1.37x against a 30% ROE; TTM EPS $2.09 vs. ~$12.48 price.
2. Earnings momentum is real: 4 straight quarters of normalized EBITDA growth; H1-2026 net income of $158M already exceeds all of FY2025 ($133M).
3. Interest burden halved after refinancing — directly flows to EPS; forward EPS of $3.33 looks achievable if zinc prices hold.
4. Equity repair: Retained losses cut by $277M in a year; tangible book compounding.
Bear case / risks:
1. Leverage: D/E of 125% and interest expense still ~$210M/yr TTM — a zinc price downturn would compress coverage quickly (2023–2024 losses show this cyclicality).
2. Liquidity: Current ratio 0.795, working capital -$297M and worsening; cash fell $136M in H1-26.
3. Commodity dependence: Revenue/EBITDA track zinc prices; Q4-25's -$0.74 EPS quarter shows downside volatility.
4. Technicals: Price below both the 50-day ($13.45) and 200-day ($12.90) averages and 26% off the $16.89 high — near-term momentum is negative despite improving fundamentals.
5. Q3-2026 results are not yet reflected in the data — the next report is a key catalyst.
Net assessment: Fundamentals have decisively inflected positive (profitability, equity rebuild, lower interest costs, positive TTM FCF) while the valuation remains deeply discounted. The leverage and working-capital risks are real but are being mitigated by earnings strength. On a pure fundamental basis, the risk/reward favors the long side, with position sizing tempered by cyclicality.
---
Maintain existing CGAU position at current size; deploy no new capital near $22. Optional modest trim into the $22.30–$22.75 resistance shelf if tactically oversized. Re-entry only on the defined triggers: fresh tactical buy on a daily close above $22.30 (volume >~1.5M, MACD crossover) with a stop below $20.60, or accumulation at $18.50–$19.00 near the 200 SMA.
The strategic case is intact — price (~$21.97) sits ~18% above a rising 200 SMA (18.56) on a zero-debt balance sheet at ~11.6x forward earnings — but the tactical setup is neutral-to-slightly-bearish: price is below the rising 50 SMA (22.30), MACD is negative despite curling up, and the 10/15 rebound to 21.97 came on weak volume (923,800) after the heavy 10/14 distribution. From $21.97 the implied risk/reward is only ~1:1 (-6.2% stop vs +6.8% target), so no new capital is justified at current levels. Hold the position and let the defined triggers do the work: a daily close above $22.30 with >1.5M shares and a MACD crossover, or an accumulation pullback into the $18.50–$19.00 zone at the 200 SMA.
1. close_200_sma (18.56): Long-term benchmark. Price sits ~18% above the 200 SMA, which is rising steadily (16.53 on 8/17 → 18.56 on 10/15). Long-term uptrend intact — no strategic damage has been done by the two-month consolidation.
2. close_50_sma (22.30): Medium-term pivot. The 50 SMA is still climbing sharply (17.07 → 22.30 over two months), but price has closed below it for the entire October pullback (10/13: 21.87; 10/14: 21.07; 10/15: 21.97 vs. 22.30). The falling-price-vs-rising-average dynamic makes 22.30 the key near-term resistance/decision line.
3. close_10_ema (21.85): Short-term timing tool. After the 10/14 washout, the 10/15 close (21.97) reclaimed the 10 EMA (21.85) — the first short-term bullish reclaim since early October. It is flattening after a steep dip, signaling momentum decay of the downswing rather than confirmed reversal.
4. macd (-0.08): Trend momentum has been negative since the late-September rollover (peak +0.517 on 9/22 → crossed zero between 10/1 and 10/2). However, the line curls upward on 10/15 (-0.0825 vs. -0.0980 on 10/14) — a potential early stabilization, not yet a signal.
5. macds (-0.03): The signal line is also negative and falling. MACD remains below its signal (bearish configuration in force since ~mid-September), but the gap is narrowing. A bullish MACD crossover, if it prints, would be the first momentum trigger of Q4 — confirmation should come with price reclaiming the 50 SMA.
6. rsi (50.11): Neutral, mid-range. RSI never reached oversold (<30) during this correction — bottoming at 41.82 (10/7) and 42.33 (10/14). That higher low in RSI against a marginal price low is mild positive divergence, but the 50 midline has capped readings repeatedly since late September. No overbought/oversold edge; RSI is a coin-flip at exactly 50.
…
4. macd (-0.08): Trend momentum has been negative since the late-September rollover (peak +0.517 on 9/22 → crossed zero between 10/1 and 10/2). However, the line curls upward on 10/15 (-0.0825 vs. -0.0980 on 10/14) — a potential early stabilization, not yet a signal.
5. macds (-0.03): The signal line is also negative and falling. MACD remains below its signal (bearish configuration in force since ~mid-September), but the gap is narrowing. A bullish MACD crossover, if it prints, would be the first momentum trigger of Q4 — confirmation should come with price reclaiming the 50 SMA.
6. rsi (50.11): Neutral, mid-range. RSI never reached oversold (<30) during this correction — bottoming at 41.82 (10/7) and 42.33 (10/14). That higher low in RSI against a marginal price low is mild positive divergence, but the 50 midline has capped readings repeatedly since late September. No overbought/oversold edge; RSI is a coin-flip at exactly 50.
7. boll_lb (20.78): The 10/14 session tagged the lower band zone (low 20.63 vs. band 20.79) and closed back inside (21.07), followed by a +4.3% rebound on 10/15 to 21.97. This is a classic lower-band rejection setup — but the band is flattening (20.78–20.95 over the past week), meaning volatility compression; band-tag bounces in flat bands often resolve into range trades, not trends. Treat ~20.60–20.80 as the tactical invalidation zone.
8. atr (0.89): Daily true range averages ~4.1% of price (0.89/21.97) — meaningful volatility for a mid-cap gold producer. Practical implications: a standard 1.5×ATR stop ≈ $20.63 (coincides with the 10/14 low); a 2×ATR stop ≈ $20.19. Position size accordingly.
The 10/14 selloff printed 2,195,800 shares — the heaviest volume since 6/18 — flagging real distribution pressure. By contrast, the 10/15 rebound came on only 923,800 shares, below the recent norm. The bounce lacks volume confirmation, which tempers conviction in an immediate recovery.
---
7. boll_lb (20.78): The 10/14 session tagged the lower band zone (low 20.63 vs. band 20.79) and closed back inside (21.07), followed by a +4.3% rebound on 10/15 to 21.97. This is a classic lower-band rejection setup — but the band is flattening (20.78–20.95 over the past week), meaning volatility compression; band-tag bounces in flat bands often resolve into range trades, not trends. Treat ~20.60–20.80 as the tactical invalidation zone.
8. atr (0.89): Daily true range averages ~4.1% of price (0.89/21.97) — meaningful volatility for a mid-cap gold producer. Practical implications: a standard 1.5×ATR stop ≈ $20.63 (coincides with the 10/14 low); a 2×ATR stop ≈ $20.19. Position size accordingly.
The 10/14 selloff printed 2,195,800 shares — the heaviest volume since 6/18 — flagging real distribution pressure. By contrast, the 10/15 rebound came on only 923,800 shares, below the recent norm. The bounce lacks volume confirmation, which tempers conviction in an immediate recovery.
---
1. BUY bias supported by fundamentals: ~$675M liquidity, near-zero debt, 27%+ ROE, forward P/E ~11.6x in a strong gold tape, and a self-funded growth pipeline.
2. Do not anchor to the 7x trailing P/E — normalized earnings (~$1.59 TTM EPS) are roughly half the headline TTM EPS ($3.15).
3. FCF is the pressure point: while capex peaks, FCF is marginal; the thesis depends on projects converting capex into production by 2027+. Any capex overrun or gold price pullback hits this leveraged-to-gold story (Beta 1.60) hard.
4. Stock is near 52-week highs (~$22 vs. $24.52 high; 200-DMA $18.64) — momentum is positive, but risk/reward favors staged entry rather than chasing.
5. Inventory build (+75% YoY) warrants monitoring — it's currently a working-capital drag; liquidation would be a future cash tailwind if it reflects real ore stockpiles.
6. Catalysts: gold price direction, project execution updates, continued buybacks, quarterly dividend (+0.92% yield).
Maintain existing position size; no adds until after the Oct 22 earnings print and only if core EPS is clean and price holds above $15.05. Size any post-earnings adds modestly (thin ~100–150k shares/day liquidity) across multiple days.
The research plan's HOLD stance matches the technical picture: FRST at $15.25 is consolidating above key support ($15.05–15.10, lower Bollinger band at 15.07) with the 200-day SMA ($14.58) intact, so the long-term uptrend is a correction away from being broken. But short-term breadth is still bearish — price below the 10-EMA (15.38), 50-SMA (15.92), and a falling VWMA, with RSI at 39 and a flattening but negative MACD — so there is no confirmed reversal entry signal either. With the Oct 22 earnings print eight days away as the decisive catalyst and no risk/reward edge between the $15.05 and $15.50 activation levels, the correct action is to maintain the position and await resolution, with a defined exit trigger if support breaks.
Maintain existing exposure at no more than half a normal small-cap starter weight; if overweight, trim into 16.90–17.40 strength before the Q3 print. Post-print: add only on confirmed triggers (close >17.36 on >100K shares, or verified organic growth + deleveraging path); hard exit on a daily close below 15.11.
The tape is a coiled, low-liquidity consolidation: price (16.46 on 2026-10-14) sits just below a rising 200 SMA (16.69), a fresh 9/23 death cross is offset by price holding above a flattening 50 SMA (16.22) inside contracting Bollinger bands (15.92–17.11) and shrinking ATR (0.50), with volume dried to 23–25K shares/day and zero directional money flow (VWMA 16.45 ≈ price). Fundamentals are equally balanced — a cheap, dividend-raising direct-sales franchise (8.8x earnings, ~5.9% trailing yield) against negative TTM free cash flow and an unverifiable +43–49% consensus EPS-growth assumption — with the decisive catalyst (Q3 organic growth, deleveraging path, dividend declaration) landing within weeks. Neither side of the debate claims to know the print outcome, and with ~25K shares/day liquidity, pre-positioning is slow to build and hard to exit; deploying or de-risking now would be a directional bet no argument supports. All discipline is embedded in the pre-committed triggers: confirm-add above 17.36 on >100K shares, hard exit on a daily close below 15.11, and Underweight/Sell on dividend or organic-growth softness.
Position Sizing: Maintain existing exposure at no more than half a normal small-cap starter weight; if overweight, trim into 16.90–17.40 strength before the Q3 print. Post-print: add only on confirmed triggers (close >17.36 on >100K shares, or verified organic growth + deleveraging path); hard exit on a daily close below 15.11.
FINAL TRANSACTION PROPOSAL: HOLD
============================================================
FINAL DECISION (BWMX, 2026-10-15):
============================================================
Hold
Elapsed: 1799s
```
…
BWMX is in a tight, low-volatility consolidation near the middle of a 12-month range after a violent January gap-up, repeated failures at the 18.40–18.89 ceiling, and a September recovery off the 15.1–15.4 floor. The current configuration is genuinely mixed: a death cross completed 2026-09-23 (50 SMA now below 200 SMA) and price (16.46) sits below the rising 200-day (16.69) — bearish on the strategic timeframe — yet price is above the 10 EMA (16.39) and 50 SMA (16.22), RSI is dead-neutral (52.19), ATR is contracting, Bollinger bands are compressing (width ≈ 7.2% of price), and volume has dried to year-lows. This is a coiling, decision-pending tape, not a trending one. Resolution direction is unknown; the asymmetry favors HOLD / wait-for-the-break, with defined triggers at ≈17.11–17.23 (upside) and ≈15.92–15.79 (downside).
Maintain existing exposure at current sizing; do not add into earnings. Future adds only on bullish trigger (reclaim of 15.04 with earnings beat), sized so an ATR-0.54 gap remains survivable.
The research plan calls for Hold into next week's binary earnings event, and the technical evidence supports not initiating: price 14.18 is in a death-cross downtrend, 17% below the 200 SMA, closed below the lower Bollinger band on heavy volume with RSI 25.8 and no confirmed reversal signal — rallies to the 15.00–15.30 supply zone are likely bearish retests until VWMA ~15.04 and the mid-band ~15.29 are reclaimed with MACD turning positive. Fundamentals (6x forward P/E, ~1.0x book, +52% yoy net income growth) argue the stock is not a short at these levels, but sponsorship is absent and SG&A is outpacing revenue, so cheap can get cheaper; both selling and buying here impose a premature directional bet ahead of earnings.
1. No confirmed reversal signal yet. Oversold RSI + lower-band break are necessary but insufficient; the trend structure (falling SMAs, price below VWMA, MACD deeply negative) remains bearish. Bullish RSI divergences at 9/23 and 9/30 lows held only ~2–3 weeks before failing.
2. Key levels: Support isundefined — the 13.91 low (10/14) is the only fresh reference; resistance sits at the Bollinger middle ~15.29, then VWMA ~15.04, then 10 EMA ~14.99, with the 15.35–15.46 early-October supply zone above.
3. Tactical setup: A watch-list scenario, not a long entry. A bounce should be confirmed by (a) RSI recovering above 30–40, (b) MACD histogram turning positive and MACD crossing its signal, and (c) volume-supported reclaim of VWMA ~15.04 and the Bollinger middle ~15.29. Without these, rallies to 15.00–15.30 are likely bearish retests.
4. Risk: ATR 0.54 means stops need at least ~1 ATR (~0.55) clearance; below 13.91 with volume, downside momentum likely extends.
5. Discrepancy note: get_indicators outputs are consistent with the verified snapshot (RSI 25.8, MACD -0.61, 50 SMA 17.02, 200 SMA 17.26, boll_lb 14.25, ATR 0.54). No conflicts found.
FINAL TRANSACTION PROPOSAL: SELL
| Indicator | Value (verified, 2026-10-14) | Reading | Implication |
|---|---|---|---|
| Close / Low | 14.18 / 13.91 | New multi-month low | Fresh support reference; break = continuation |
| 200 SMA | 17.26 | Price -17.8% below | Long-term bearish; declines still defeating it |
| 50 SMA | 17.02 | Price below; SMA falling | Confirms persistent downtrend |
| 10 EMA | 14.99 | Price below | Short-term momentum still down |
| RSI | 25.8 | Oversold | Bounce risk but no divergence confirmed |
| MACD / Histogram | -0.61 / +0.02 (pre-drop) | Negative & widening again | Deceleration stalled; no bullish cross |
| Bollinger LB / Mid | 14.25 / 15.29 | Close below lower band | Extreme oversold; breaks often continue in downtrends |
| ATR | 0.54 (~3.8%) | Elevated | Size positions accordingly; wide stops |
| VWMA (20d) | 15.04 | Price far below, rising volume on down days | No accumulation signature |
| 200 SMA vs 50 SMA | 17.26 > 17.02 | Death-cross configuration | Structural bearish confirmation |
================================ Human Message =================================
…
Trim existing ALLY exposure by one-third to one-half; if flat, stay flat (no new position before October 20 earnings)
The research plan lands on Underweight, and the technical report explains how to execute it: ALLY is deeply oversold (RSI 23.55, price $0.92 above the lower Bollinger Band at $36.70), creating a high-probability mean-reversion bounce toward the $39.72 VWMA and $40.57 20 SMA — but the dominant trend is confirmed bearish via the 50/200 SMA death cross at $42.27–$42.31, accelerating MACD histogram, and high-volume institutional distribution. Rather than dumping into weakness at $37.62, I will use the expected bounce to trim exposure by one-third to one-half at the $39.72 VWMA, the first major volume-weighted supply zone, with the 10 EMA at $38.92 capping early bounce attempts. A protective stop at $42.35 (just above the 50/200 SMA confluence) keeps the position intact through the secondary trim window at $40–$42 if the bounce extends, since that zone is a wall of underwater buyers rather than a breakout signal. Residual position should tolerate a 25–30% drawdown, and no adds are permitted ahead of the October 20 earnings event, where the bear case (debt-funded buybacks, +31% QoQ insurance/claims expense signaling auto credit stress, hostile long-end rate backdrop) argues the downside asymmetry outweighs re-rating upside. Full exit is triggered on a high-volume breakdown below $36.70 or deteriorating charge-off guidance.
The clearest positive institutional signal is the Simply Wall St article arguing that ALLY could be approximately 22% undervalued based on its auto-lending push. The article notes a strong 66.7% three-year return while acknowledging that the shares have recently been under pressure. This is an explicitly valuation-oriented, mildly bullish thesis, although it is article framing rather than confirmed company guidance or an analyst price target.
Two other items are directionally negative but lack sufficient detail to quantify:
A 24/7 Wall St. roundup identifies ALLY as one of Wednesday’s notable Wall Street research calls, but the available text does not disclose the analyst, rating change, or price-target direction. It should therefore be treated as evidence of analyst attention, not as clearly bullish or bearish evidence. The same roundup highlights rising Treasury yields as a market headwind.
News direction: Slightly positive on valuation and auto lending, but balanced by rate sensitivity, volatility warnings, and unresolved analyst-call details.
Only 3 messages were returned:
The single tagged Bearish message from 2026-09-29 is substantive. It reports that ALLY slid 1.55% and argues that rising long-term rates are a direct headwind for a digital auto-finance and banking business because they can compress net interest margins and weaken auto-loan demand. It also flags Q3 earnings on October 20. This is the most detailed source-level signal, but one message is not enough to establish a broad retail consensus.
The two unlabeled posts are more ambiguous. The 2026-10-01 message says ALLY is “back on watch,” with the daily chart approaching a possible double bottom and a potential swing setup. Language such as “buy low” and “sell on gap ups” suggests opportunistic tactical interest rather than clear directional conviction. The other message is chart-only and provides no readable thesis.
StockTwits direction: Mixed to mildly bearish because the only explicit label is Bearish, while the more recent unlabeled post points to a possible technical rebound setup.
Reddit could not be fetched from r/wallstreetbets, r/stocks, or r/investing. This is explicitly a collection failure, not evidence that ALLY was absent from discussion. No Reddit sentiment, attention, upvote, or engagement conclusions can be drawn.
The main divergence is between fundamental-value framing and near-term macro/rate concern. News coverage includes a claim that ALLY may be undervalued and supported by its auto-lending strategy, while the tagged StockTwits message argues that the same rate environment creating market pressure is directly negative for net interest margins and auto-loan demand. These are not necessarily contradictory: a longer-term valuation case can coexist with near-term earnings pressure.
There is also alignment between the news and StockTwits on Treasury-yield sensitivity. The 24/7 Wall St. roundup highlights rising yields, and the Bearish StockTwits post directly links them to margin compression and weaker loan demand.
Retail sentiment is not strongly contrarian because the sample is only three messages. The most recent unlabeled post hints at a possible double-bottom swing trade, but it is not enough to offset the explicit Bearish macro message.
1. Rising rates and net-interest-margin pressure: The clearest recurring theme across news and StockTwits. This is currently the dominant near-term risk narrative for ALLY.
2. Auto lending as both opportunity and exposure: The valuation article frames auto lending as a reason ALLY could be undervalued, while the Bearish post sees weaker auto-loan demand as a consequence of higher rates.
3. Recent share-price pressure versus potential rebound: News notes underperformance, while the latest StockTwits post is watching for a possible double bottom and swing trade.
4. Event-driven uncertainty: Inclusion in a Wall Street research-calls roundup and the approaching October 20 earnings date increase the potential for sentiment to shift quickly.
5. Longer-term digital/AI disruption risk: Agentic AI could affect customer-traffic control, though the supplied excerpt does not provide a company-specific magnitude.
Potential catalysts
Key risks
…
Ally Financial Inc. is a leading U.S. digital financial services company headquartered in Detroit, Michigan. Its core businesses include:
Ally's business model is highly rate-sensitive: it earns net interest income on its large auto loan book (~$140.5B net loans) and pays market-rate interest on its deposit base. Its profitability trajectory is therefore closely tied to the Federal Reserve rate cycle, credit conditions in the auto market, and funding costs.
---
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2,544M | $2,353M | $2,362M | $2,370M | $2,283M |
| Net Interest Income | $1,953M | $1,857M | $1,854M | $1,809M | $1,732M |
| Net Income | $410M | $319M | $327M | $398M | $352M |
| Diluted EPS | $1.18 | $0.93 | $0.95 | $1.18 | $1.04 |
| Efficiency (Op. Margin, TTM) | ~25.3% | | | | |
Notable observations:
| Year | Total Revenue | Net Interest Income | Net Income | Diluted EPS |
|---|---|---|---|---|
| FY2025 | $8,770M | $7,113M | $852M | $2.37 |
| FY2024 | $8,897M | $6,750M | $668M | $1.80 |
| FY2023 | $9,070M | $7,061M | $957M | $2.98 |
| FY2022 | $9,240M | $7,764M | $1,715M | $5.03 |
Analysis:
---
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Assets | $199.8B | $197.3B | $196.0B | $191.7B | $189.5B |
| Net Loans | $140.5B | $136.7B | $134.5B | $131.3B | $130.0B |
| Total Equity | $15.49B | $15.61B | $15.50B | $15.12B | $14.55B |
| Tangible Book Value | $13.33B | $13.10B | $12.98B | $12.60B | $12.03B |
| Total Debt | $22.3B | $21.1B | $21.3B | $20.2B | $18.9B |
| Cash & Equivalents | $7.84B | $9.52B | $10.03B | $10.25B | $10.59B |
Key observations:
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total Assets | $196.0B | $191.8B | $196.3B | $191.8B |
| Net Loans | $134.5B | $132.5B | $136.3B | $132.7B |
| Total Equity | $15.50B | $13.90B | $13.70B | $12.86B |
| Tangible Book Value | $12.98B | $10.97B | $10.64B | $9.62B |
TBV has grown at an ~11% CAGR since 2022, reflecting consistent profitability (even during the earnings trough) and disciplined capital management.
---
| Metric | Q2 2026 | Q1 2026 |
|---|---|---|
| Operating Cash Flow | $1,353M | $1,371M |
| Free Cash Flow | $629M | $666M |
| Capital Expenditure | -$724M | -$705M |
| Stock Repurchases | -$1,498M | -$147M |
| Common Dividends Paid | -$92M | -$102M |
| Net Debt Issuance | +$1,469M | -$312M |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating Cash Flow | $3,729M | $4,528M | $4,557M | $6,247M |
| Free Cash Flow | -$546M | $1,068M | $1,798M | $2,715M |
Analysis:
---
| Metric | Value |
|---|---|
| Market Cap | ~$11.44B |
| P/E (TTM) | 8.85x |
| Forward P/E | 5.92x |
| PEG Ratio | 0.27 |
| Price / Book | 0.85x |
| EPS (TTM) | $4.25 |
| Forward EPS | $6.35 |
| Dividend Yield | 3.19% |
| Beta | 1.074 |
| Book Value / Share | $44.38 |
| 52-Week High / Low | $47.29 / $35.92 |
| 50-Day Avg / 200-Day Avg | $42.45 / $42.77 |
Key takeaway: ALLY trades at a ~15% discount to book value with a single-digit trailing P/E and an exceptionally low forward P/E of 5.9x (implying ~50% earnings growth expectations). The PEG of 0.27 suggests the market is significantly underpricing the embedded earnings recovery.
---
Maintain the existing SKHY weight only if it fits the risk cap: with beta 2.39 and ATR $8.69 (~5.9% daily), size so the ~15% fall to the $124.80 stop costs no more than 1–2% of the portfolio — if current weight exceeds that cap, trim mechanically regardless of directional view. No adds before the late-October Q3 print (event discipline); any future adds only in 25–33% tranches per the escalation playbook, toward the $164.9–170.8 resistance shelf.
The research plan calls for Hold: best-in-cycle fundamentals (₩79.3T Q2 revenue +257% YoY, 83.2% gross margin, net-cash balance sheet, ~11x normalized earnings) are offset by peak-cycle multiple risk, low earnings quality (₩60.9T of net income from mark-to-market gains on an ₩85.3T AI-concentrated portfolio), and a technically confirmed downtrend — with the late-October Q3 print as the resolution event, so pre-committing new capital is a coin flip, not an edge. We therefore maintain existing exposure but do not add at ~$146.11 while price sits below all four MAs (10 EMA 164.87 / 200 SMA 166.53 / 50 SMA 170.81 / VWMA 171.28) with MACD accelerating (histogram -5.45) and down-day volume expanding (33.75M). Risk is capped mechanically per the plan: with ATR $8.69 and beta 2.39, position size is set so a decline to the $124.80 stop (the last verifiable July demand shelf, ~-15% from current price) stays within a 1–2% portfolio impact. Direction defers to the pre-written playbook: escalate to staged adds on a clean Q3 print plus 2+ confirmations (close back inside the Bollinger bands, close above the 10 EMA ~$165, MACD histogram contracting 2+ sessions, fading down-volume); de-risk fully on sequential revenue decline, >10pt margin compression, confirmed HBM price cuts/portfolio markdowns, or a decisive close below $124.80.
SKHY has transitioned violently from a multi-month uptrend into a high-velocity breakdown. The stock printed a peak close of $198.63 on 2026-09-09 and has since collapsed to $146.11 (2026-10-15) — a -26.4% drawdown from the peak, including an 8-consecutive-session losing streak from 10-06 through 10-15 (verified closes) and a -25.1% decline in just 8 trading days from the $195.02 close on 10-05. Price now sits below every major moving average (10 EMA, 50 SMA, 200 SMA, VWMA) and below the lower Bollinger Band, with MACD deeply negative and accelerating downward, RSI near oversold at 31.03, and volume rising on down days (33.75M on 10-15 vs. a ~10–20M norm in late September).
The alignment of trend (bearish), momentum (bearish, accelerating), volatility (elevated and re-expanding), and volume (distribution) supports a SELL / avoid-long exposure stance. The only nuance: statistically stretched conditions (close below lower band, RSI ≈ 31, a strong intraday recovery off the 10-15 low) make a sharp counter-trend bounce plausible — but no reversal confirmation exists yet (no bullish MACD crossover, no RSI divergence, no reclaim of the 10 EMA). Oversold is not a buy signal in a confirmed downtrend.
---
The topping process and breakdown, from verified closes:
| Phase | Dates (2026) | Verified evidence |
|---|---|---|
| Peak zone / triple-top area | 09-09 → 10-05 | Closes of 198.63 (09-09), 195.37 (09-22), 195.13 (10-02), 195.02 (10-05) — three failed approaches to the 195–199 zone |
| Breakdown onset | 10-06 → 10-09 | Closes 182.56 → 178.25 → 170.50 → 169.03; the 10-06 bar gapped/fell from 195.02 to 182.56 |
| Acceleration | 10-12 → 10-15 | Closes 162.23 → 157.06 → 147.55 → 146.11; volume expands 14.7M → 22.2M → 23.7M → 33.75M |
Key structural facts (all tool-verified):
---
1. Anchor to normalized earnings (₩125.8T TTM / $34.48 forward EPS), not headline NI — core P/E of ~11x is the honest multiple.
2. The imminent Q3 2026 print is the event risk/catalyst. Watch: (a) sequential revenue and HBM pricing, (b) inventory (₩18.0T) absorption, (c) capex guidance creep, (d) tax payments on the gains.
3. Technical/fundamental divergence favors accumulation: price ~15% under the 200-DMA with net-cash balance sheet and 4x forward earnings is historically an asymmetric setup — consider staged entries rather than a single position, given beta 2.39.
4. Treat the investment portfolio as a side-pocket: if the ₩85.3T FVPL book marks down, headline EPS volatility will be extreme even if the core business is fine — don't mistake accounting noise for demand deterioration.
5. Stop-out discipline: a fundamental break (sequential revenue decline, gross margin down >10 pts QoQ, or HBM price cuts) would invalidate the thesis regardless of how cheap the multiple looks.
---
Maintain current position at existing target size; do not add. Conservative sizing given unproven post-acquisition returns — no more than current allocation, and reduce promptly on a volume-confirmed break below 46.56 (particularly if accompanied by weak Q3 results). For reference, with ATR at 1.04, a stop at 46.50 is roughly 1.2x ATR from current price, allowing standard volatility-based sizing.
EQBK is in a corrective phase within an intact long-term uptrend: price (47.73) sits above the rising 200-day SMA (46.73) and the 46.56–46.73 confluence support, but below the 10 EMA (47.88) and falling 50 SMA (49.67) with a negative, deepening MACD — confirming the correction is not yet resolved. Fundamentally, the bull case (record Q2 EPS of $1.27, 48.4% NII growth, 8.7x forward P/E, buybacks) is offset by volatile quarterly earnings, 4.9% reported ROE, negative AOCI, and 16% goodwill/intangibles, making the cheap valuation unproven until Q3 confirms the earnings run rate. With no position, staying sidelined is right; with a position, the operational momentum and intact support argue against exiting before Q3 results. Hold at current size, honor the hard review trigger at 46.50 (just under the 46.56 confluence), and only consider a measured add after Q3 confirms ≥$1.20 EPS with stable credit costs and a reclaim of 50.76.
EQBK is in a confirmed intermediate-term downtrend within a still-intact long-term uptrend. After a strong multi-month advance that peaked near 51.86 (2026-08-14 high), the stock has pulled back approximately 8% and is now consolidating just above the 200-day SMA. Price sits below both the 10 EMA and 50 SMA but remains above the rising 200 SMA — a classic bull-market correction rather than a full trend reversal. Momentum indicators are weak-to-neutral (RSI 39.5, negative and deepening MACD), and volatility has cooled considerably from summer levels.
Bottom line: This is a corrective phase in an uptrend. The key battleground is the 46.56–46.73 zone (Bollinger lower band + 200 SMA), which defines the line between a healthy pullback and a deeper breakdown.
---
EQBK has appreciated from ~39.68 (2025-10-01 close) to 47.73 (2026-10-02 close) — roughly a 20% gain over twelve months. The 200-day SMA stands at 46.73 and has been rising steadily since July (44.13 on 2026-07-06 → 46.73 on 2026-10-02), confirming the secular uptrend remains in place. The stock has traded above its 200 SMA since approximately April 2026.
The stock peaked at 51.86 on 2026-08-14 and has since entered a persistent downtrend of lower highs and lower lows:
The last three sessions show a modest base forming near 47:
This small two-day bounce from the September 30 low of 46.74 is potentially constructive, but it needs to clear the 10 EMA at 47.88 to gain credibility.
---
RSI has been trending lower since mid-September (51.3 on 09-14 → 31.4 on 09-30), with a modest recovery to 39.5 on 10-02. The reading is:
The RSI low of 31.4 on 2026-09-30 was the most oversold reading since early September (31.2 on 09-23), suggesting some downside momentum exhaustion — but the bounce in RSI is weak and needs follow-through.
The MACD line has been negative and trending lower since late August, when it peaked at +0.81 (08-06). Key observations:
No bullish crossover yet. Traders should watch for the MACD line to cross back above the signal line — this would be a meaningful short-term buy signal.
---
| Band | Value (10-02) |
|---|---|
| Upper Band | 50.83 |
| Middle Band (20 SMA) | 48.69 |
| Lower Band | 46.56 |
| Band Width | ~$4.27 (~8.8% of price) |
Price at 47.73 sits in the lower half of the band range. The stock tested the lower band on 2026-09-30 (low of 46.74, close of 47.14) and has since moved slightly higher. The lower band at 46.56 coincides almost exactly with the 200 SMA at 46.73, creating a confluence support zone between 46.56 and 46.73.
ATR has declined sharply from summer peaks of ~1.30 (late July) to the current 1.04. This contraction in volatility suggests:
---
| Level | Price | Basis |
|---|---|---|
| Resistance 2 | 50.83 | Bollinger upper band; also the 51.86 Aug high zone |
| Resistance 1 | 49.67 | 50-day SMA; major overhead supply |
| Pivot | 48.69 | 20-day SMA (Bollinger middle) |
| Immediate | 47.88 | 10-day EMA |
| Support 1 | 46.56–46.73 | Bollinger lower band + 200-day SMA confluence |
| Support 2 | 46.02–46.74 | October 1 low / September 30 low |
| Support 3 | 44.50–45.00 | July consolidation zone / gap area |
---
| Risk | Severity | Probability | Mitigation |
|---|---|---|---|
| Fed hikes in Oct or Dec despite jobs miss | Medium | 18% (Oct) | Diversified deposit base |
| CRE credit deterioration | Medium | Moderate | Conservative underwriting |
| Deposit competition re-intensifies | Low-Medium | Low in near term | Relationship banking focus |
| Regulatory changes | Low | Low | Deregulatory trend |
| Broader market correction | Medium | Low-Medium (8% recession) | Strong capital position |
---
With all retrieved sources silent, the sentiment read for EQBK over 2026-09-26 to 2026-10-03 is Neutral (score 5.0) with low confidence. This is a data-scarcity verdict, not a conviction: it reflects an absence of measured sentiment, not a positive or negative view. There is no evidence of retail over-extension or speculative froth, but equally no evidence of institutional endorsement or any fresh catalyst. A trader should treat this report as uninformative on direction and rely on fundamentals, technicals, and upcoming calendar items (e.g., any scheduled earnings or Fed/rate events) rather than sentiment signals. Past sentiment, where present, is not predictive of future price.
================================ Human Message =================================
Proceed with your assigned analysis for this workflow. The instrument to analyze is `EQBK`. Use this exact ticker in every tool call, report, and recommendation, preserving any exchange suffix (e.g. `.TO`, `.L`, `.HK`, `.T`, `-USD`). Resolved identity: Company: Equity Bancshares, Inc.; Business classification: Financial Services / Banks - Regional; Exchange: NYQ. Do not substitute a different company or ticker unless a tool result explicitly disproves this resolved identity. The analysis date is 2026-10-03.
================================== Ai Message ==================================
I'll analyze EQBK (Equity Bancshares) from multiple angles: company news, macro environment, and forward-looking market expectations.
Tool Calls:
get_news (tool_ADzF0Qtu3xp7dAd8wVXhucxn)
Call ID: tool_ADzF0Qtu3xp7dAd8wVXhucxn
Args:
ticker: EQBK
start_date: 2026-09-26
end_date: 2026-10-03
get_global_news (tool_y1m9cGG3eoht18UVeT6VHghQ)
Call ID: tool_y1m9cGG3eoht18UVeT6VHghQ
Args:
curr_date: 2026-10-03
look_back_days: 7
get_macro_indicators (tool_5dHSgOf0JSSPK94MxA0rlmQV)
Call ID: tool_5dHSgOf0JSSPK94MxA0rlmQV
Args:
indicator: fed_funds_rate
curr_date: 2026-10-03
get_macro_indicators (tool_1X5JFYuq7q6ZoyrrLNbO7KI3)
Call ID: tool_1X5JFYuq7q6ZoyrrLNbO7KI3
Args:
indicator: 10y_treasury
curr_date: 2026-10-03
================================= Tool Message =================================
Name: get_macro_indicators
…
---